Check out this new report by Visiongain - Global infusion devices market forecast 2018 2028

50 %
50 %
Information about Check out this new report by Visiongain - Global infusion devices market...

Published on October 31, 2018

Author: Visiongain

Source: slideshare.net

1. www.visiongain.com Page 67 Global Infusion Devices Market Forecast 2018-2028: Syringe, Insulin, Volumetric, Ambulatory, Patient Controlled Analgesia, Implantable, Enteral, Gastroenterology, Diabetes, Analgesia & Pain Management, Chemotherapy, Paediatrics & Neonatology, Hospital, Home Healthcare, Ambulatory Surgical Centres 3.8.1 Global Infusion Devices Market, Implantable Infusion Pumps Revenue Forecast, 2018-2028 The implantable infusion pumps in the global infusion devices market by product type, has achieved total revenue of $75.9m in 2017. In 2018, there would be a growth of 6.9%; revenue will reach $81.1m, Visiongain predicts. Revenue will reach from $81.1m in 2018 to $111.1m in 2023, with an increasing compound annual growth rate of 6.5%. The CAGRs for the period 2023-2028 and 2018- 2028 are expected to be 5.4% and 6.0% respectively (Table 3.7). Table 3.7 Global Implantable Infusion Pumps: Revenue ($m), AGR (%) and CAGR (%) 2017-2028 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 Implantable Infusion Pumps 75.9 81.1 86.6 92.3 98.4 104.6 111.1 117.8 124.6 131.4 138.2 144.9 Annual Growth (%) 6.9 6.8 6.7 6.5 6.4 6.2 6.0 5.8 5.5 5.2 4.8 CAGR (%) 2018-2023 & 2023-2028 6.5 5.4 CAGR (%) 2018-2028 6.0 Figure 3.7 Global Implantable Infusion Pumps: Revenue ($m), 2017-2028 0.0 20.0 40.0 60.0 80.0 100.0 120.0 140.0 160.0 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 Revenue($m) Year Source: Visiongain 2018 Source: Visiongain 2018

2. www.visiongain.com Page 95 Global Infusion Devices Market Forecast 2018-2028: Syringe, Insulin, Volumetric, Ambulatory, Patient Controlled Analgesia, Implantable, Enteral, Gastroenterology, Diabetes, Analgesia & Pain Management, Chemotherapy, Paediatrics & Neonatology, Hospital, Home Healthcare, Ambulatory Surgical Centres Table 5.5 Global Other End User Segment: Revenue ($m), AGR (%) and CAGR (%) 2017-2028 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 Other End User 359.3 378.6 398.4 418.8 439.7 460.8 482.2 503.5 524.5 544.9 564.5 582.7 Annual Growth (%) 5.4 5.2 5.1 5.0 4.8 4.6 4.4 4.2 3.9 3.6 3.2 CAGR (%) 2018-2023 & 2023- 2028 5.0 3.9 CAGR (%) 2018-2028 4.4 Figure 5.5 Global Other End User Segment: Revenue ($m), 2017-2028 5.6 Segment Share Analysis by End User According to Visiongain estimates, hospitals was the world’s largest market among the end user of infusion devices in 2017 with sales of $990.5m representing 46.0% share of the global market. Followed by hospitals segment was ambulatory surgical centres (ASCs), with sales worth $529.4m in 2017, representing 24.6% share of the global market. In 2028, the home healthcare segment is expected to generate sales of $601.5m, with a share of 15.2% of the global market with a rise from 14.1% in 2023. 0.0 100.0 200.0 300.0 400.0 500.0 600.0 700.0 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 Revenue($m) Year Source: Visiongain 2018 Source: Visiongain 2018

3. www.visiongain.com Page 142 Global Infusion Devices Market Forecast 2018-2028: Syringe, Insulin, Volumetric, Ambulatory, Patient Controlled Analgesia, Implantable, Enteral, Gastroenterology, Diabetes, Analgesia & Pain Management, Chemotherapy, Paediatrics & Neonatology, Hospital, Home Healthcare, Ambulatory Surgical Centres 7.1.3 Financial Highlights Table 7.2 Baxter: Revenue ($m), R&D Expenses ($m), 2015-2017 2015 2016 2017 Net Revenue 9,968.0 10,163.0 10,561.0 Research & Development Expenses 617 647 603 7.1.4 Recent Strategic Developments Table 7.3 Baxter Recent Developments Month & Year Development Type Description May 2018 Product approval Baxter received FDA clearance for New Spectrum IQ Infusion System with Dose IQ Safety Software. This device is enabled to deliver medications and fluids to the patients and automatically document infusion data into the EMR. January 2018 Product launch Baxter launched Arisure Closed System Transfer device, developed to ensure drug preparation, transportation, administration, and disposal. September 2017 Product launch Baxter launched DeviceVue, an end-to-end asset tracking application. It is an asset-tracking solution used with the Sigma Spectrum Infusion System that is designed to help in enhancing clinical and hospital efficiency. DeviceVue enable clinicians and biomedical engineers to rapidly find unused pumps by viewing pump location and status data from their PC, iPad, or iPhone. December 2016 Product launch Baxter launched Sigma Spectrum Safety Management System, which was developed to add features that help to minimize infusion programming risks. This software solution provides advanced infusion data analysis and graphical reporting to help detect pump programming errors. In addition, it provides regular cybersecurity monitoring and reporting. Source: Company’s Website, Visiongain 2018 Source: Company’s Website, Visiongain 2018

Add a comment